Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
ENGN Stock Chart & Stats
$9.34
$0.17(2.19%)
At close: 4:00 PM EST
$9.34
$0.17(2.19%)
Day’s Range― - ―
52-Week Range$2.65 - $11.14
Previous CloseN/A
Volume16.79K
Average Volume (3M)246.99K
Market Cap
$609.56M
Enterprise Value$526.36M
Total Cash (Recent Filing)$193.81M
Total Debt (Recent Filing)$31.80M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Mar 16, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding66,984,660
10 Day Avg. Volume307,519
30 Day Avg. Volume246,985
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.03K
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$23.75Price Target Upside154.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationNon-viral delivery and emerging LEGEND results, together with a favorable safety profile, suggest a competitive clinical profile that could differentiate the therapy from late-stage rivals.
Practical Administration And Commercial RolloutOff-the-shelf intravesical administration with straightforward storage and preparation mirrors established BCG workflows and lowers logistical barriers for community urology practices, supporting faster real-world uptake.
Regulatory PathwayPlans to file a biologics license application for detalimogene combined with selection into FDA development readiness programs indicate regulatory engagement that could streamline approval readiness and reduce program execution risk.
Bears Say
Commercial Adoption RiskLater entry to the market relative to competitors could hinder commercial adoption, making payor access and uptake in urology practices more challenging.
Data Maturity RiskInterim response rates may change as additional data accrues, creating potential volatility in efficacy readouts and investor expectations.
Durability UncertaintyDurability of complete responses remains unclear and longer-term outcomes will be essential to benchmark effectiveness against approved therapies.
enGene Holdings News
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $2.65 and its highest was $11.14 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $609.56M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Mar 16, 2026 which is in 52 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Dec 22, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.567 by -$0.163.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on enGene Holdings dividends here
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.56.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 66,984,660 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.567. Following the earnings report the stock price went up 5.131%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
enGene Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.75 (154.28% Upside)
$23.75 (154.28% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 108.6%
Last 30 Days ▲ 108.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.00%
12-Months-Change
Fundamentals
Return on Equity
-53.28%
Trailing 12-Months
Asset Growth
-28.83%
Trailing 12-Months
Company Description
enGene Holdings
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$23.75
▲(154.28% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Replimune Group
―
Immuneering
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
4.47%
Insiders
0.17% Mutual Funds
54.41% Other Institutional Investors
40.86% Public Companies and Individual Investors
Options Prices
Currently, No data available
---